IO Biotech expands collaboration with MSD – begins phase II trial

Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech begins phase III trial with partner MSD
For subscribers
MSD Covid-19 treatment less effective than first thought
For subscribers